Updates are available Correction dated 2023-06-30

Article History

Received: 21 December 2022

Accepted: 26 April 2023

First Online: 8 May 2023

Change Date: 30 June 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s40814-023-01347-6

Declarations

:

: The Erase Hep C study was approved by the University of Texas at Austin’s Institutional Review Board (IRB), as well as CommUnityCare’s Research and Quality Improvement Committee. This protocol was submitted in two parts to the IRB. Any significant protocol amendments of how site-specific HCV treatment workflows are implemented will be submitted as modifications to the IRB and updated on ClinicalTrials.gov. Written voluntary informed consent will be obtained from potential study participants for the baseline qualitative interviews and at the time of enrollment into the trial by the research coordinator or research assistant. We also obtained a Certificate of Confidentiality from the National Institutes of Health (NIH) for all study participants.We do not anticipate any serious adverse events. We expect any adverse events or harms to study participation to be related to risk of data breach or risk of uncomfortableness and inconvenience of time. For data and safety monitoring, any data breaches and any such social harms will be reported to the UT IRB. The participants’ safety will be monitored by the clinic, as per the standard of care.

: Not applicable.

: The authors declare that they have no competing interests.